Would you treat or monitor a patient with low HBV DNA levels and high ALT? Here’s my take.
Who are the rare patients with hepatitis B infection who can benefit from peginterferon? Here’s my take.
When should we recommend waiting vs starting treatment in women planning to conceive and those who are already in the early or late stages of pregnancy?
Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Dynavax Technologies, Gilead Sciences, and Novartis and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.
How do renal dysfunction, insurance coverage, and long-term safety concerns affect whether we should recommend TAF, TDF, or entecavir to our patients starting HBV therapy?
Patients with low levels of HBV DNA are at greater risk of HCC, particularly those with cirrhosis. Read how I evaluate for causes of low-level viremia and manage patients in this situation.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.